What is ExPeCT™ anti-CD19 (FMC63) CAR T's cybersecurity risk score?

ExPeCT™ anti-CD19 (FMC63) CAR T has an AI-generated cybersecurity risk score of 755 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has ExPeCT™ anti-CD19 (FMC63) CAR T experienced?

According to Rankiteo, ExPeCT™ anti-CD19 (FMC63) CAR T currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has ExPeCT™ anti-CD19 (FMC63) CAR T been affected by any supply chain cyber incidents ?

According to Rankiteo, ExPeCT™ anti-CD19 (FMC63) CAR T has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does ExPeCT™ anti-CD19 (FMC63) CAR T have SOC 2 Type 1 certification ?

According to Rankiteo, ExPeCT™ anti-CD19 (FMC63) CAR T is not certified under SOC 2 Type 1.

Does ExPeCT™ anti-CD19 (FMC63) CAR T have SOC 2 Type 2 certification ?

According to Rankiteo, ExPeCT™ anti-CD19 (FMC63) CAR T does not hold a SOC 2 Type 2 certification.

Does ExPeCT™ anti-CD19 (FMC63) CAR T comply with GDPR ?

According to Rankiteo, ExPeCT™ anti-CD19 (FMC63) CAR T is not listed as GDPR compliant.

Does ExPeCT™ anti-CD19 (FMC63) CAR T have PCI DSS certification ?

According to Rankiteo, ExPeCT™ anti-CD19 (FMC63) CAR T does not currently maintain PCI DSS compliance.

Does ExPeCT™ anti-CD19 (FMC63) CAR T comply with HIPAA ?

According to Rankiteo, ExPeCT™ anti-CD19 (FMC63) CAR T is not compliant with HIPAA regulations.

Does ExPeCT™ anti-CD19 (FMC63) CAR T have ISO 27001 certification ?

According to Rankiteo,ExPeCT™ anti-CD19 (FMC63) CAR T is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does ExPeCT™ anti-CD19 (FMC63) CAR T operate in ?

ExPeCT™ anti-CD19 (FMC63) CAR T operates primarily in the Medical and Diagnostic Laboratories industry.

How many employees does ExPeCT™ anti-CD19 (FMC63) CAR T have ?

ExPeCT™ anti-CD19 (FMC63) CAR T employs approximately 0 people worldwide.

Does ExPeCT™ anti-CD19 (FMC63) CAR T own any subsidiaries ?

ExPeCT™ anti-CD19 (FMC63) CAR T presently has no subsidiaries across any sectors.

How many LinkedIn followers does ExPeCT™ anti-CD19 (FMC63) CAR T have ?

ExPeCT™ anti-CD19 (FMC63) CAR T's official LinkedIn profile has approximately 84 followers.

Does ExPeCT™ anti-CD19 (FMC63) CAR T have a Crunchbase profile ?

No, ExPeCT™ anti-CD19 (FMC63) CAR T does not have a profile on Crunchbase.

Does ExPeCT™ anti-CD19 (FMC63) CAR T have a LinkedIn profile ?

Yes, ExPeCT™ anti-CD19 (FMC63) CAR T maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/expectassay.

How many cybersecurity incidents has ExPeCT™ anti-CD19 (FMC63) CAR T experienced ?

As of June 22, 2026, Rankiteo reports that ExPeCT™ anti-CD19 (FMC63) CAR T has not experienced any cybersecurity incidents.

How many peer or competitor companies does ExPeCT™ anti-CD19 (FMC63) CAR T have ?

ExPeCT™ anti-CD19 (FMC63) CAR T has an estimated 166 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

EAC

Boost Score +25 with badge (5 left)

755

/1000

Fair

780

/1000

Fair

ExPeCT™ anti-CD19 (FMC63) CAR T Vendor Cyber Rating & Cyber Score

eurofins-viracor.com

Add Your Compliance Badge

Innovations in Immunity The ExPeCT anti-CD19 CAR T assay is an intervention tool which allows the Clinical team to provide patient care by directly monitoring the effectiveness of CAR T-cell therapy * Assess current immune response * Expansion and persistence of CAR T-cells * Evaluate treatment decisions

EAC A.I CyberSecurity Scoring

Scoring History

EAC

ExPeCT™ anti-CD19 (FMC63) CAR T CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

EAC Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for EAC

Incidents vs Medical and Diagnostic Laboratories Industry Avg (This Year)

No incidents recorded for ExPeCT™ anti-CD19 (FMC63) CAR T in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for ExPeCT™ anti-CD19 (FMC63) CAR T in 2026.

Incident Types EAC vs Medical and Diagnostic Laboratories Industry Avg (This Year)

No incidents recorded for ExPeCT™ anti-CD19 (FMC63) CAR T in 2026.

Incident History - EAC (X = Date, Y = Severity)

Loading…

SUBSIDIARY

ExPeCT™ anti-CD19 (FMC63) CAR T Subsidiaries

EAC

Medical and Diagnostic Laboratories

Website: https://www.eurofins-viracor.com/clinical/our-testing/car-t/?utm_source=social&utm_medium=Lishowcase&utm_campaign=CARt

Company Size: 0

EurofinsBiotechnology Research

Eurofins Clinical Trial SolutionsBiotechnology Research

Eurofins Lancaster LaboratoriesBiotechnology Research

Eurofins PSS Insourcing SolutionsBiotechnology Research

Eurofins BioPharma Product Testing ItalyPharmaceutical Manufacturing

Eurofins AdvinusResearch Services

Eurofins Discovery Services IndiaResearch

Eurofins Advinus Agrosciences IndiaResearch Services

Eurofins BioPharma Product Testing India Pharmaceutical Manufacturing

Eurofins Agroscience ServicesResearch

Eurofins Agroscience Seed ServicesResearch Services

Eurofins Agroscience Biological SolutionsResearch

Eurofins Agroscience Regulatory ConsultancyResearch Services

Eurofins Agroscience Biological AssessmentResearch Services

Eurofins Agroscience Consumer/Human SafetyResearch Services

Eurofins Agroscience Environmental SafetyResearch

Eurofins Agroscience Product ChemistryResearch Services

Eurofins do Brasil Análises de Alimentos e AmbientaisResearch Services

Eurofins IT Delivery CenterIT Services and IT Consulting

Eurofins Food AssuranceProfessional Services

Eurofins GenomicsBiotechnology Research

Eurofins BiomnisMedical and Diagnostic Laboratories

Eurofins Environment Testing (USA)Environmental Services

Eurofins Environment Testing FranceBiotechnology

Eurofins | Solutions DurablesServices de conseil en environnement

Eurofins Hygiène HospitalièreBiotechnology Research

Eurofins Central LaboratoryBiotechnology Research

Eurofins Analyses Alimentaires FranceBiotechnology Research

Eurofins Biopharma Product Testing (France)Pharmaceutical Manufacturing

Eurofins DiscoveryBiotechnology

Eurofins US Food, Feed, & Supplement TestingBiotechnology Research

Eurofins Danmark - LaboratoriumBiotechnology Research

Eurofins Steins LaboratoriumBiotechnology Research

Eurofins Product Testing Denmark A/SSecurity and Investigations

Eurofins CDMOPharmaceutical Manufacturing

Eurofins CDMO AlphoraPharmaceutical Manufacturing

Eurofins Clinical DiagnosticsBiotechnology

Eurofins ChileFood and Beverage Services

Eurofins Food, Feed & Water BeneluxBiotechnology Research

Eurofins DiscoverXBiotechnology Research

Eurofins Agro & HortiResearch Services

Eurofins Genomics AmericasBiotechnology

Eurofins CanadaBiotechnology Research

DiatherixBiotechnology Research

Eurofins Environment BeneluxEnvironmental Services

Eurofins Viracor CMV TestingBiotechnology Research

Eurofins ViracorMedical and Diagnostic Laboratories

TTViWATCH™ - Torque Teno Virus qPCRMedical and Diagnostic Laboratories

Loading…

ExPeCT™ anti-CD19 (FMC63) CAR T Similar Companies

Quest Diagnostics

cb questdiagnostics.com

Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion. Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories. Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients. Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions. The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals. More information is available at www.questdiagnostics.com. Language Assistance / Non-Discrimination Notice Asistencia de Idiomas / Aviso de no Discriminación 語言協助 / 不歧視通知 www.QuestDiagnostics.com/home/nondiscrimination

Dasa

cb dasa.com.br

A Dasa é uma das maiores empresas de saúde do mundo, líder em medicina diagnóstica no Brasil. Trabalha para transformar sua especialização, alcance e escala em acesso à saúde de qualidade e cuidado humanizado. A empresa faz parte da vida de mais de 20 milhões de pessoas por ano, com alta tecnologia, amplo portfólio de exames e serviços e foco na melhor experiência em saúde. Com mais de 25 mil colaboradores e mais de 350 mil médicos parceiros, processa mais de 414 milhões de exames por ano em suas mais de 40 marcas presentes em todo o território nacional. Essa capilaridade única torna a Dasa a companhia de saúde que mais se relaciona com as pessoas, oferecendo soluções conectadas à realidade e à diversidade do país. Com uma governança baseada em gestão disciplinada e capacidade de execução, a empresa avança como uma organização inovadora, focada e sustentável, sempre pautada pela excelência médica e pelo compromisso com a sustentabilidade do setor da saúde.

Loading…

NEWS

ExPeCT™ anti-CD19 (FMC63) CAR T CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-12814

SUMMARY

A flaw has been found in Comfast CF-WR631AX V3 up to 2.7.0.8. This issue affects the function system of the file /cgi-bin/mbox-config?section=ping_config of the component API Endpoint. This manipulation of the argument destination causes os command injection. The attack is possible to be carried out remotely. The exploit has been published and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-21

Updated

Date2026-06-21

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-12813

SUMMARY

A vulnerability was detected in activepieces up to 0.83.0. This vulnerability affects the function handleUrlFile in the library packages/server/engine/src/lib/variables/processors/file.ts of the component File URL Handler. The manipulation results in server-side request forgery. The attack can be executed remotely. The exploit is now public and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-21

Updated

Date2026-06-21

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-12812

SUMMARY

A security vulnerability has been detected in Radware Cyber Controller up to 10.11.0. This affects an unknown part of the component HTML Report Generation. The manipulation leads to HTML injection. Remote exploitation of the attack is possible. The exploit has been disclosed publicly and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-21

Updated

Date2026-06-21

RISK INFORMATION (Score: 3.5)

cvss2

Base Score: 4.0

Complexity: LOW

AV:N/AC:L/Au:S/C:N/I:P/A:N

cvss3

Base Score: 3.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:N/I:L/A:N

cvss4

Base Score: 2.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.1

REFERENCES

CVE-2026-12811

SUMMARY

A weakness has been identified in kortix-ai suna up to 0.8.38. Affected by this issue is the function router.replace/router.push of the file apps/frontend/src/app/auth/page.tsx of the component Auth Endpoint. Executing a manipulation of the argument returnURL can lead to cross site scripting. The attack may be launched remotely. The exploit has been made available to the public and could be used for attacks. Upgrading to version 0.8.39 can resolve this issue. This patch is called f5dec7aa0c1b8fa0125938f292c0f2430ca75f6c. It is advisable to upgrade the affected component. The researcher explains: "The issue was fixed in v0.8.39 without notifying the wider user base via a security disclosure."

Published

Date2026-06-21

Updated

Date2026-06-21

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:N/I:P/A:N

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-12810

SUMMARY

A security flaw has been discovered in Edimax BR-6478AC V2 1.23. Affected by this vulnerability is the function mp of the file /goform/mp of the component POST Request Handler. Performing a manipulation of the argument command results in command injection. The attack may be initiated remotely. The exploit has been released to the public and may be used for attacks. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-21

Updated

Date2026-06-21

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…